Pharmacologic management of metabolic and alcohol-associated liver disease
Metabolism and Target Organ Damage · 16.06.2026 · 6 (2)
DOI: 10.20517/mtod.2026.29 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolism and Target Organ Damage, online erschienen am 16.06.2026. Verfasst von Mangesh Pagadala und 3 weiteren Autor:innen. Beteiligte Einrichtung: Liver Institute, Methodist Dallas Medical Center, Dallas, TX 75203, USA. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
Metabolic dysfunction and Alcohol associated Liver Disease (MetALD) is an emerging phenotype within the steatotic liver disease spectrum, characterized by cardiometabolic risk factors coexisting with alcohol exposure, resulting in synergistic liver injury and fibrosis progression. Therapeutic development remains limited because most steatotic liver disease trials exclude patients with ongoing alcohol use. In contrast, alcohol-associated liver disease (ALD) trials have focused primarily on severe alcohol-associated hepatitis. Current management of patients with MetALD relies on an integrated approach that simultaneously controls alcohol use and cardiometabolic risk. In clinical practice, for patients with MetALD and ongoing alcohol use, therapies aimed at controlling alcohol use remain most critical, given the faster, more progressive disease course related to alcohol as compared to metabolic liver injury. Given the dynamic nature of alcohol intake and metabolic risk factors, longitudinal monitoring of disease stage with noninvasive fibrosis tests is essential. Liver-directed therapies with efficacy in metabolic dysfunction-associated steatotic liver disease (MASLD), including incretin-based agents, fibroblast growth factor 21 analogs, peroxisome proliferator-activated receptor agonists, and thyroid hormone receptor beta agonists, may benefit selected MetALD patients. Several agents may modulate both metabolic pathways and alcohol consumption through central reward mechanisms. Specific pharmacotherapies targeting alcohol use (acamprosate, naltrexone) combined with structured psychosocial interventions are effective in controlling alcohol use. Given the lack of dedicated clinical trials in MetALD patients, we synthesized data from clinical trials in MASLD and ALD. We propose adapting these data to inform the design of future clinical trials in patients with MetALD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Institute, Methodist Dallas Medical Center, Dallas, TX 75203, USA.
- Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA 94305, USA.
- Pembroke Hill School, Kansas City, MO 64112, USA.
- Division of Gastroenterology Hepatology and Nutrition, University of Louisville School of Medicine, Louisville, KY 40202, USA.
Förderung
- NIGMS NIH HHS
- NIAAA NIH HHS
Zitieren
APA
Pagadala, M., Jalil, S., Dunn, N., & Singal, A. K. (2026). Pharmacologic management of metabolic and alcohol-associated liver disease. Metabolism and Target Organ Damage, 6(2). https://doi.org/10.20517/mtod.2026.29
Vancouver
Pagadala M, Jalil S, Dunn N, Singal AK. Pharmacologic management of metabolic and alcohol-associated liver disease. Metabolism and Target Organ Damage. 2026;6(2). doi:10.20517/mtod.2026.29
BibTeX
@article{Pagadala2026,
author = {Pagadala, Mangesh and Jalil, Sajid and Dunn, Nicholas and Singal, Ashwani K},
title = {Pharmacologic management of metabolic and alcohol-associated liver disease},
journal = {Metabolism and Target Organ Damage},
year = {2026},
volume = {6},
number = {2},
doi = {10.20517/mtod.2026.29}
}
EUVIMED